

Docket No. 2026-4266US1

IN THE UNITED STATES

[] RECEIVING OFFICE (RO/US)
 [X] DESIGNATED OFFICE (DO/US)
 [X] ELECTED OFFICE (EO/US)

#3

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US98/19794	22 September 1998 (22.09.98)	10 October 1997 (10.10.97)
TITLE OF INVENTION		
AGONIST AND ANTAGONIST PEPTIDES OF		
CARCINOEMBRYONIC ANTIGEN (CEA)		
APPLICANT(S)		
Jeffrey SCHLOM, et al.		

Commissioner for Patents
 Box PCT
 Washington, D.C. 20231

Attention: DO/EO/US

VERIFIED CERTIFICATION OF EXPRESS MAILING DATE
 (INTERNATIONAL APPLICATION (37 CFR 1.10(c)))

I declare that on 13 June 2000 I deposited with the United States Postal Service in an envelope "Express Mail, Post Office to Addressee", bearing Label Number EK784974056US, addressed to the "Commissioner of Patents and Trademarks, Washington, D.C. 20231" and having an express mail certification which I executed, the following papers:

Response to Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US); Executed Combined Declaration and Power of Attorney; Copy of the Notification; Change of Correspondence Address; Associate Power of Attorney; Check for \$130.00 (surcharge fee) and Return Postcard.

A copy of these papers from the file of this application is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

06/19/2000 PVOLPE 00000055 09529121


01 FC:154

130.00 OP

Date 13 June 2000

Albert Isles

(Typed or printed name of person making this verified statement)



(Signature of person making this verified statement)

(Verified Certification of Express Mailing Date (International Application) [13-12])

FORM PTO-1100 (REV. 10-96)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	APPLICANT'S DOCKET NUMBER 2026-4266US1
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/529121
INTERNATIONAL APPLICATION NO. PCT/US98/19794	INTERNATIONAL FILING DATE 22 September 1998 (22.09.98)	PRIORITY DATE CLAIMED 10 October 1997 (10.10.97)	
TITLE OF INVENTION AGONIST AND ANTAGONIST PEPTIDES OF CARCINOEMBRYONIC ANTIGEN (CEA)			
APPLICANT(S) FOR DO/EO/US Jeffrey SCHLOM, et al.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.			
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).			
b. <input type="checkbox"/> has been transmitted by the International Bureau.			
c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).			
6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).			
b. <input type="checkbox"/> have been transmitted by the International Bureau.			
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.			
d. <input type="checkbox"/> have not been made and will not be made.			
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Unsigned)			
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11. to 16. below concern document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. <input type="checkbox"/> A FIRST preliminary amendment.			
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
14. <input type="checkbox"/> A substitute specification.			
15. <input type="checkbox"/> A change of power of attorney and/or address letter.			
16. <input checked="" type="checkbox"/> Other items or information:			
- Copy of the first page of the published international application # WO 99/19478			
- Copy of the International Preliminary Examination Report			
- Copy of Response to Invitation to Furnish Nucleotide And/Or Amino Acid Sequence Listing, with a computer readable copy of the sequence listing in ASCII format			

APPLICATION NO. 09/529121		INTERNATIONAL APPLICATION NO. PCT/US98/19794		422-Rec'd PCT/PTO 06 APR 2000		ATTORNEY'S INDEX NUMBER 2026-4266US1	
17 <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY			
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):							
Search Report has been prepared by the EPO or JPO				\$840.00	840.00		
International preliminary examination fee paid to USPTO (37 CFR 1.482)				\$670.00			
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))				\$690.00			
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$970.00			
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)				\$ 96.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 840.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE				
Total claims	197 - 20 =	177	X\$18.00	\$3,186.00			
Independent claims	5 - 3 =	2	X\$78.00	\$ 156.00			
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+\$260.00	\$ 260.00			
TOTAL OF ABOVE CALCULATIONS =				\$			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$4,442.00			
SUBTOTAL =				\$4,442.00			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$			
TOTAL NATIONAL FEE =				\$4,442.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$			
TOTAL FEES ENCLOSED =				\$4,442.00			
				Amount to be: refunded	\$		
				charged	\$		
a. <input checked="" type="checkbox"/> A check in the amount of \$ 4,442.00 to cover the above fees is enclosed.							
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-4500. A duplicate copy of this sheet is enclosed.							
Order No. 2026-4266US1							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPONDENCE TO							
William S. Feiler							
Morgan & Finnegan, L.L.P.							
345 Park Avenue							
New York, New York 10154							
Telephone No. (212) 758-4800							
Facsimile No. (212) 751-6849							
				SIGNATURE			
				William S. Feiler			
				NAME			
				26,728			
				REGISTRATION NUMBER			